#United States #New York #Securities Fraud #Wolf Haldenstein #Charming Medical

Important Notice for Shareholders of Charming Medical Ltd.

Investors who have experienced financial losses related to their shares in Charming Medical Ltd. (NASDAQ: MCTA) should be alert and act promptly to explore their legal options. Wolf Haldenstein Adler Freeman & Herz LLP, a renowned law firm with over 125 years of experience, has recently acknowledged a significant federal securities class action filed on behalf of affected shareholders. This lawsuit pertains to investors who purchased Charming Medical securities during the defined class period ranging from October 21, 2025, to November 12, 2025.

Background of the Case

The class action lawsuit comes in light of alarming allegations regarding the company’s stock price, which reportedly surged from $4.00 per share to a staggering $29.36 purely based on misleading social media promotions, lacking any substantial company developments to justify such an increase. As per the allegations, this abrupt price increase was driven by a fraudulent stock promotion scheme heavily reliant on social media platforms where impersonators posed as financial advisors, disseminating unfounded claims aimed at baiting unsuspecting retail investors.

Subsequently, these dubious trading practices led to a suspension of trading in Charming Medical's securities in November 2025, revealing the artificial nature of previous price increases and leaving countless investors grappling with significant losses.

Legal Timeline and Considerations

The deadline for investors wishing to step forward as lead plaintiffs is set for February 17, 2026. This timeframe is crucial for affected shareholders to assess their losses and comprehend how to proceed legally. Wolf Haldenstein invites any investor whose financial standing was compromised to reach out to discuss potential participation in the class action lawsuit.

Why Wolf Haldenstein?

Choosing Wolf Haldenstein means enlisting a firm with a solid track record of advocating for the rights of investors. Their expertise in securities litigation is well-established, providing reassurance to those affected by this unfortunate turn of events. Investors are encouraged to take action before the lead plaintiff deadline passes, ensuring their voices are heard throughout the legal proceedings.

Contact Information for Interested Parties

For those looking to connect with Wolf Haldenstein, the firm can be reached via:

• - Phone: (800) 575-0735 or (212) 545-4774
• - Email: [email protected]
• - Contact Person: Gregory Stone, Director of Case and Financial Analysis.

For more detailed information, detailing participation options in the class action, warm invitations are extended through their official website.

This situation serves as a stark reminder of the inherent risks associated with stock investments, especially when influenced by unverified promotional strategies. Investors are advised to remain vigilant and informed about the securities they choose to engage with, ensuring that they are not led astray by misleading information or schemes.